Welcome to our dedicated page for Cardiol Therapeu news (Ticker: CRDL), a resource for investors and traders seeking the latest updates and insights on Cardiol Therapeu stock.
Cardiol Therapeutics Inc. (CRDL) is a clinical-stage biopharmaceutical company pioneering novel therapies for inflammatory heart diseases through its innovative cannabidiol-based formulations. This page provides investors and medical professionals with essential updates on clinical trials, regulatory milestones, and research developments.
Our curated news collection offers immediate access to peer-reviewed study results, FDA communications, and strategic partnership announcements. Track progress across Cardiol's pipeline including CardiolRx™ for recurrent pericarditis and CRD-38 for myocardial fibrosis – therapies targeting critical inflammatory pathways through advanced nanodelivery systems.
Key updates include Phase II/III trial outcomes, scientific presentations at cardiology conferences, and manufacturing advancements. All content is vetted for accuracy and presented in chronological order to help stakeholders monitor the company's progress in addressing unmet needs in cardiovascular care.
Bookmark this page for streamlined access to Cardiol's latest developments in anti-inflammatory drug research. For comprehensive analysis of how these updates may impact therapeutic landscapes and investment considerations, consult your financial advisor.
Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) has announced the completion of its MAvERIC Phase II study for recurrent pericarditis. The full clinical data will be presented at the American Heart Association Scientific Sessions 2024 on November 18, 2024. The study investigated the impact of CardiolRx™ on patients with symptomatic recurrent pericarditis. The primary endpoint data showed marked reductions in pericarditis pain and inflammation at 8 weeks. The study involved 27 adult participants across eight U.S. clinical sites and consisted of an 8-week treatment period followed by an 18-week extension period. The presentation will include additional endpoints such as freedom from pericarditis recurrence, 26-week pain scores, inflammatory marker levels, and safety outcomes.
Cardiol Therapeutics (NASDAQ: CRDL, TSX: CRDL) held its annual general and special meeting of shareholders on June 26, 2024. Shareholders voted in favor of all proposed management resolutions. Key resolutions included the re-election of eight directors and the appointment of BDO Canada LLP as auditors. Additionally, the unallocated awards under Cardiol's Omnibus Equity Incentive Plan were approved. The re-elected directors are David Elsley, Peter Pekos, Dr. Guillermo Torre-Amione, Colin Stott, Michael Willner, Jennifer Chao, Chris Waddick, and Teri Loxam. The voting results showed strong support, with directors receiving between 96.01% and 99.66% of the votes cast.
Cardiol Therapeutics (NASDAQ: CRDL, TSX: CRDL) has announced that its Annual General and Special Meeting of Shareholders will be held virtually on June 26, 2024, at 4:30 p.m. EDT. The meeting will be accessible via a live audio webcast at web.lumiagm.com/253136217. During this event, shareholders can participate and vote on various matters. Cardiol is a clinical-stage company dedicated to developing anti-inflammatory and anti-fibrotic therapies for heart disease. Further details on the AGM and participation instructions are available on Cardiol's investor website.
Cardiol Therapeutics announced positive topline data from its Phase II MAvERIC-Pilot study, evaluating CardiolRxTM for treating recurrent pericarditis. The 8-week clinical data showed a significant reduction in pericarditis pain and inflammation. The study involved 27 patients, and 89% continued into the extension phase. Notably, 80% of patients with elevated CRP levels at baseline showed normalization. The primary endpoint revealed a mean pain reduction of 3.7 on the NRS scale. CardiolRxTM was well-tolerated and appears promising for future Phase III trials.
Cardiol Therapeutics presented its Phase II ARCHER trial at the World Congress on Acute Heart Failure 2024. The trial is evaluating CardiolRx™ in patients with acute myocarditis. The presentation included the trial design, rationale, and baseline data on the first 50 patients randomized.
The ARCHER trial has exceeded 85% of target enrollment, with a target of 100 patients across multiple countries. Its primary measures are cardiac MRI assessments of left ventricular function and myocardial edema/fibrosis. The MAvERIC-Pilot Phase II study for recurrent pericarditis is expected to report topline results in June 2024.
Acute myocarditis is a severe inflammatory condition with significant health risks. Cardiol's CEO highlighted the growing interest in myocarditis treatments and the contributions of clinical collaborators to the study's progress.
FAQ
What is the current stock price of Cardiol Therapeu (CRDL)?
What is the market cap of Cardiol Therapeu (CRDL)?
